- Stocks
- Pharma & Healthcare
- Dr Lalchandani
Dr Lalchandani share price
NSE: DLCLPharma & HealthcareDiagnostics & Research
Dr Lalchandani at a glance
With a market capitalisation of ₹7 Cr, it ranks 3994th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Diagnostics & Research.
Its return on equity was 4.2% in FY25. In Q4 FY24, the quarter ended 31 Mar 2024, revenue was ₹2 Cr and net profit ₹1 Cr, on a standalone basis. Promoters held 32.90% of the company as of 31 Mar 2026.
Key numbers
- Market cap
- ₹7 CrRank 3994 on NSE
- Price to book
- 0.45×FY25
- ROE
- 4.2%FY25
- ROCE
- 3.6%FY25
- Debt to equity
- 0.41FY25
- Net profit margin
- 9.4%FY25
- Book value / share
- ₹22.94FY25
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | — | — | — | — | — |
Dr Lalchandani quarterly results
| Quarter | Q3 FY24 | Q4 FY24 |
|---|---|---|
| Revenue | — | ₹2 Cr |
| Revenue YoY | — | — |
| Net profit | — | ₹1 Cr |
| Net profit YoY | — | — |
| Net margin | — | 34.1% |
| EPS | — | ₹1.63 |
Dr Lalchandani financials
| Item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Revenue | ₹6 Cr | ₹10 Cr | ₹11 Cr | ₹5 Cr | ₹5 Cr | ₹4 Cr |
| Operating profit | ₹1 Cr | ₹1 Cr | ₹1 Cr | −₹2 Cr | −₹1 Cr | ₹0 Cr |
| Net profit | ₹0 Cr | ₹1 Cr | ₹1 Cr | −₹2 Cr | ₹1 Cr | ₹0 Cr |
| EPS (₹) | ₹1.09 | ₹2.33 | ₹2.15 | −₹3.61 | ₹1.43 | ₹0.96 |
| Cash from operations | −₹0 Cr | ₹1 Cr | ₹2 Cr | ₹0 Cr | −₹0 Cr | ₹0 Cr |
| Total debt | ₹1 Cr | ₹3 Cr | ₹3 Cr | ₹3 Cr | ₹0 Cr | ₹0 Cr |
| Shareholders' equity | ₹9 Cr | ₹10 Cr | ₹10 Cr | ₹9 Cr | ₹10 Cr | ₹10 Cr |
Dr Lalchandani shareholding pattern
| Holder | 31 Mar 2024 | 30 Sep 2024 | 31 Mar 2025 | 30 Sep 2025 | 10 Mar 2026 | 31 Mar 2026 |
|---|---|---|---|---|---|---|
| Promoters | 60.78% | 57.18% | 48.32% | 31.15% | 32.90% | 32.90% |
| Non-institutions | 39.22% | 42.82% | 51.68% | 68.85% | 67.10% | 67.10% |
Dr Lalchandani vs peers
The listed Pharma & Healthcare companies nearest to Dr Lalchandani by market capitalisation.
Ask anything about Dr Lalchandani
Pivot answers on the live chart with evidence you can check, and tests strategies against DLCL's own history. Try: “Why has DLCL moved over the last three months?” · “Backtest a 50-day moving-average crossover on DLCL over five years” · “Compare DLCL with TRINITYLEA on margins and valuation”
Frequently asked questions about Dr Lalchandani
What is the market cap of Dr Lalchandani?
Dr Lalchandani's market capitalisation is ₹7 Cr (₹7 Cr) at the 22 Oct 2026 close, ranking 3994th among the NSE companies Pivot tracks.
What is the ROE and ROCE of Dr Lalchandani?
Return on equity was 4.2% in FY25 and return on capital employed was 3.6% in FY25 (standalone figures).
Is Dr Lalchandani a debt-free company?
No. Dr Lalchandani's debt-to-equity ratio was 0.41 in FY25, with total debt of ₹0 Cr.
What were Dr Lalchandani's latest quarterly results?
For Q4 FY24 (quarter ended 31 Mar 2024), Dr Lalchandani reported revenue of ₹2 Cr and net profit of ₹1 Cr.
What is the shareholding pattern of Dr Lalchandani?
As of 31 Mar 2026: promoters 32.90%, non-institutions 67.10%.
Who are Dr Lalchandani's competitors?
The listed Pharma & Healthcare companies closest to Dr Lalchandani by market cap are Trinity League, Adline Chem Lab, Unjha Formula, Vivanza Bio, DECIPHER LABS and Evoq Remedies.
Is Dr Lalchandani a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Dr Lalchandani's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on DLCL against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, standalone where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with D · all NSE stocks · this page as text